Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-812 (Qelbree) in adults with ADHD
NCT04016779Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing SPN-812 with Placebo (2 arms). Primary endpoint: Adult ADHD Investigator Symptom Rating Scale Total Score at 6 weeks. Started Nov 2019; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04016779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016779.